Cargando…
The C-C Chemokine Receptor Type 4 Is an Immunomodulatory Target of Hydroxychloroquine
The emergence of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; COVID-19) in China, reported to the World Health Organization on December 31, 2019, has led to a large global pandemic and is a major public health issue. As a result, there are more than 200 clinical trials of COVID-19...
Autores principales: | Beck, Tyler C., Beck, Kyle R., Holloway, Calvin B., Hemings, Richard A., Dix, Thomas A., Norris, Russell A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482581/ https://www.ncbi.nlm.nih.gov/pubmed/32973504 http://dx.doi.org/10.3389/fphar.2020.01253 |
Ejemplares similares
-
Immunomodulatory biomaterials on chemokine signaling in wound healing
por: Apte, Anisha, et al.
Publicado: (2023) -
C-C chemokine receptor-7 mediated endocytosis of antibody cargoes into intact cells
por: Charest-Morin, Xavier, et al.
Publicado: (2013) -
C-C chemokine receptor type 5 links COVID-19, rheumatoid arthritis, and Hydroxychloroquine: in silico analysis
por: Hachim, Mahmood Y., et al.
Publicado: (2020) -
Trace Amine-Associated Receptors as Novel Therapeutic Targets for Immunomodulatory Disorders
por: Christian, Sherri L., et al.
Publicado: (2018) -
Editorial: Chemokine receptors and signaling in wound healing
por: Chen, Zhenlong, et al.
Publicado: (2023)